In vitro cytotoxicity and in vivo distribution after direct delivery of PEG-camptothecin conjugates to the rat brain

被引:59
作者
Fleming, AB
Haverstick, K
Saltzman, WM
机构
[1] Yale Univ, Dept Biomed Engn, Becton Ctr 227, New Haven, CT 06511 USA
[2] Cornell Univ, Sch Chem & Biomol Engn, Ithaca, NY 14853 USA
关键词
D O I
10.1021/bc034180o
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Low water solubility and rapid elimination from the brain inhibits local delivery via implants and other delivery systems of most therapeutic drugs to the brain. We have conjugated the chemotherapy drug, camptothecin (CPT), to poly(ethylene glycol) (PEG) of molecular weight 3400 using previously established protocols. These new conjugates are very water-soluble and hydrolyze at a pH-dependent rate to release the active parent drug. We have studied the uptake of these conjugates by cells in vitro and quantified their cytotoxicity toward gliosarcoma cells. These conjugates were loaded into biodegradable polymeric controlled-release implants, and their release characteristics were studied in vitro. We implanted similar polymeric disks into rat brains and used a novel sectioning scheme to determine the concentration profile of CPT in comparison to conjugated CPT in the brain after 1, 7, 14, and 28 days. We have found that PEGylation greatly increases the maximum achievable drug concentration and greatly enhances the distribution properties of CPT, compared to corelease of CPT with PEG. Although only one percent of CPT in the conjugate system was found in the hydrolyzed, active form, drug concentrations were still significantly above cytotoxic levels over a greater distance for the conjugate system. On the basis of these results, we believe that PEGylation shows great promise toward increasing drug distribution after direct, local delivery in the brain for enhanced efficacy in drug treatment.
引用
收藏
页码:1364 / 1375
页数:12
相关论文
共 30 条
[1]   Polymer-bound camptothecin: initial biodistribution and antitumour activity studies [J].
Caiolfa, VR ;
Zamai, M ;
Fiorino, A ;
Frigerio, E ;
Pellizzoni, C ;
d'Argy, R ;
Ghiglieri, A ;
Castelli, MG ;
Farao, M ;
Pesenti, E ;
Gigli, M ;
Angelucci, F ;
Suarato, A .
JOURNAL OF CONTROLLED RELEASE, 2000, 65 (1-2) :105-119
[2]  
CARTLIDGE S A, 1986, Journal of Controlled Release, V3, P55, DOI 10.1016/0168-3659(86)90064-7
[3]  
Conover CD, 1997, ANTICANCER RES, V17, P3361
[4]   Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker [J].
Conover, CD ;
Greenwald, RB ;
Pendri, A ;
Gilbert, CW ;
Shum, KL .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1998, 42 (05) :407-414
[5]  
Conover CD, 1999, ANTI-CANCER DRUG DES, V14, P499
[6]   DEXTRAN RETENTION IN THE RAT-BRAIN FOLLOWING RELEASE FROM A POLYMER IMPLANT [J].
DANG, WB ;
SALTZMAN, WM .
BIOTECHNOLOGY PROGRESS, 1992, 8 (06) :527-532
[7]  
DANG WB, 1994, CANCER RES, V54, P1729
[8]  
Duncan R, 1996, STP PHARMA SCI, V6, P237
[9]   H-1-AND C-13-NMR SPECTRA OF CAMPTOTHECIN AND DERIVATIVES [J].
EZELL, EL ;
SMITH, LL .
JOURNAL OF NATURAL PRODUCTS, 1991, 54 (06) :1645-1650
[10]  
Fung LK, 1998, CANCER RES, V58, P672